NZ595467A - Sublingual pharmaceutical composition comprising a neutral oil - Google Patents
Sublingual pharmaceutical composition comprising a neutral oilInfo
- Publication number
- NZ595467A NZ595467A NZ595467A NZ59546710A NZ595467A NZ 595467 A NZ595467 A NZ 595467A NZ 595467 A NZ595467 A NZ 595467A NZ 59546710 A NZ59546710 A NZ 59546710A NZ 595467 A NZ595467 A NZ 595467A
- Authority
- NZ
- New Zealand
- Prior art keywords
- medicament
- oil
- composition
- pharmaceutical composition
- neutral oil
- Prior art date
Links
- 230000007935 neutral effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 abstract 2
- 229960002428 fentanyl Drugs 0.000 abstract 2
- 125000005456 glyceride group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical group [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 abstract 1
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/050416 WO2010122276A1 (en) | 2009-04-23 | 2009-04-23 | Drug delivery |
| GB0906977A GB2469792A (en) | 2009-04-23 | 2009-04-23 | Oil-based pharmaceutical formulation for sublingual delivery |
| PCT/GB2010/050671 WO2010122355A1 (en) | 2009-04-23 | 2010-04-23 | Sublingual pharmaceutical composition comprising a neutral oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595467A true NZ595467A (en) | 2013-08-30 |
Family
ID=42236683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595467A NZ595467A (en) | 2009-04-23 | 2010-04-23 | Sublingual pharmaceutical composition comprising a neutral oil |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120058158A1 (https=) |
| EP (1) | EP2421503A1 (https=) |
| JP (1) | JP2012524771A (https=) |
| CN (1) | CN102458358A (https=) |
| AU (1) | AU2010240653A1 (https=) |
| BR (1) | BRPI1013539A2 (https=) |
| CA (1) | CA2756879A1 (https=) |
| IL (1) | IL215454A (https=) |
| MX (1) | MX2011010835A (https=) |
| MY (1) | MY167918A (https=) |
| NZ (1) | NZ595467A (https=) |
| RU (1) | RU2011139638A (https=) |
| SG (1) | SG175160A1 (https=) |
| WO (1) | WO2010122355A1 (https=) |
| ZA (1) | ZA201107089B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US20130254139A1 (en) * | 2012-03-21 | 2013-09-26 | Xiaoguang Lei | Systems and methods for building a universal intelligent assistant with learning capabilities |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US10376586B2 (en) | 2016-02-16 | 2019-08-13 | Entourage Bioscience, LLC | Method and compositions for solubilizing non-polar constituents |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| KR20230137362A (ko) * | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| KR102442753B1 (ko) * | 2016-12-26 | 2022-09-16 | 셀릭스 바이오 프라이빗 리미티드 | 만성 통증 치료를 위한 화합물 |
| IL313551A (en) * | 2017-09-27 | 2024-08-01 | Aquestive Therapeutics Inc | Enhanced delivery epinephrine and prodrug compositions |
| EP3902523A1 (en) | 2018-12-29 | 2021-11-03 | 3M Innovative Properties Company | Oral articles and methods of use |
| WO2020136606A1 (en) | 2018-12-29 | 2020-07-02 | 3M Innovative Properties Company | Oral articles and methods of use |
| HUE073311T2 (hu) * | 2020-03-31 | 2026-01-28 | Remicine Ip B V | Hiperinflammatorikus szindróma kezelése |
| EP4422607A4 (en) | 2021-10-25 | 2025-09-03 | Aquestive Therapeutics Inc | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4869899A (en) * | 1986-03-10 | 1989-09-26 | Walter Burghart | Pharmaceutical preparation and process for producing the same |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| DK1361864T3 (en) * | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| RU2432950C2 (ru) * | 2006-01-25 | 2011-11-10 | Инсис Терапьютикс Инк. | Подъязычный спрей на основе фентанила |
| CA2698752A1 (en) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| NZ595469A (en) * | 2009-04-23 | 2013-10-25 | Londonpharma Ltd | Sublingual spray formulation comprising dihydroartemesinin |
-
2010
- 2010-04-23 JP JP2012506583A patent/JP2012524771A/ja active Pending
- 2010-04-23 US US13/265,825 patent/US20120058158A1/en not_active Abandoned
- 2010-04-23 EP EP10715336A patent/EP2421503A1/en not_active Withdrawn
- 2010-04-23 CA CA2756879A patent/CA2756879A1/en not_active Abandoned
- 2010-04-23 CN CN2010800179717A patent/CN102458358A/zh active Pending
- 2010-04-23 BR BRPI1013539A patent/BRPI1013539A2/pt not_active Application Discontinuation
- 2010-04-23 SG SG2011073939A patent/SG175160A1/en unknown
- 2010-04-23 MX MX2011010835A patent/MX2011010835A/es active IP Right Grant
- 2010-04-23 NZ NZ595467A patent/NZ595467A/xx not_active IP Right Cessation
- 2010-04-23 WO PCT/GB2010/050671 patent/WO2010122355A1/en not_active Ceased
- 2010-04-23 RU RU2011139638/15A patent/RU2011139638A/ru unknown
- 2010-04-23 AU AU2010240653A patent/AU2010240653A1/en not_active Abandoned
- 2010-04-23 MY MYPI2011005079A patent/MY167918A/en unknown
-
2011
- 2011-09-28 ZA ZA2011/07089A patent/ZA201107089B/en unknown
- 2011-10-02 IL IL215454A patent/IL215454A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MY167918A (en) | 2018-09-27 |
| BRPI1013539A2 (pt) | 2016-04-12 |
| IL215454A (en) | 2014-11-30 |
| MX2011010835A (es) | 2012-05-08 |
| ZA201107089B (en) | 2012-12-27 |
| CN102458358A (zh) | 2012-05-16 |
| AU2010240653A1 (en) | 2011-10-20 |
| WO2010122355A1 (en) | 2010-10-28 |
| RU2011139638A (ru) | 2013-05-27 |
| JP2012524771A (ja) | 2012-10-18 |
| US20120058158A1 (en) | 2012-03-08 |
| CA2756879A1 (en) | 2010-10-28 |
| IL215454A0 (en) | 2011-12-29 |
| EP2421503A1 (en) | 2012-02-29 |
| SG175160A1 (en) | 2011-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MY194947A (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| MX2011013201A (es) | Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
| MY149731A (en) | Compounds | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| MX2009009131A (es) | Mejoras en y con relacion a composiciones medicinales. | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| MY157307A (en) | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbersartan | |
| MX2011011829A (es) | Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico. | |
| IN2014DN01619A (https=) | ||
| NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
| MX2009009134A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2011006797A (es) | Una formulación para administración oral transmucósica de fármacos reductores de lípidos. | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
| UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
| WO2011035343A3 (en) | Phentermine liquid dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 APR 2017 BY DENNEMEYER SA Effective date: 20140314 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2018 BY DENNEMEYER + CO Effective date: 20170427 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2019 BY DENNEMEYER + CO Effective date: 20180420 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2020 BY PAVIS GMBH Effective date: 20190410 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2021 BY PAVIS GMBH Effective date: 20200514 |
|
| LAPS | Patent lapsed |